| Date | Title | | | Mar 08, 2010 | FDA Approves NerPharMa to Manufacture Cell Therapeutics' Drug Pixantrone| SEATTLE, March 8, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that the U.S. Food and Drug Administration ("FDA") has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTI has a New Drug ... |
|  | | Mar 04, 2010 | Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority| GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212
SEATTLE, March 4, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO(TM) used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the... |
| | | Mar 01, 2010 | FDA Sets March 22 for ODAC Meeting to Review CTI's New Drug Application for Pixantrone| SEATTLE, March 1, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010. The meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather condit... |
| | | Feb 26, 2010 | Cell Therapeutics Announces Filing of Form 10-K| SEATTLE, Feb 26, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2009 (the "Annual Report on Form 10-K"). This filing is available for review on CTI's website at www.CellTherapeutics.com, or on the Securities and Exchange Commission's website at www.sec.gov.
As required under NASDAQ Marketplace Rule 5250(b)(2), CTI also announced that its consolidated financial ... |
| | | Feb 11, 2010 | Cell Therapeutics, Inc. (CTI) Decreases Net Loss by 42% in 2009| SEATTLE, Feb 11, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2009.
Review of 2009 Key Accomplishments and Targeted 2010 Milestones
Pixantrone New Drug Application ("NDA") for relapsed/refractory aggressive non-Hodgkin's lymphoma filed with the U.S. Food and Drug Administration (the "FDA") and accepted for review in 2009. The FDA establishe... |
| | | Feb 09, 2010 | FDA Postpones Oncologic Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe Weather Conditions| SEATTLE, Feb 09, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration (the "FDA") informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule t... |
| | | Feb 08, 2010 | Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2009 Financial Results on February 11| SEATTLE, Feb 08, 2010 /PRNewswire via COMTEX/ -- On Thursday, February 11, 2010, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 fourth quarter and year-end achievements and financial results.
Conference Call Numbers
Thursday, February 11
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-9... |
| | | Jan 13, 2010 | Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants| SEATTLE, Jan 13, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 3 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors. Each share of Series 3 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 823 shares of common stock ... |
| | | Jan 11, 2010 | Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference| SEATTLE, Jan 11, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 28th Annual JP Morgan Healthcare Conference in San Francisco. The conference will be held January 11-14, 2010, at the Westin St. Francis. CTI will present on Thursday, January 14, 2010, 2:00 PM Pacific Time. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
... |
| |
|
